Envoy Medical, Inc. stockholders approved an amendment authorizing the Board of Directors, at its discretion, to effect one or more reverse stock splits of Class A common stock at a ratio from 1-for-5 to 1-for-25, at any time through December 31, 2026. The first proposal received 44,012,206 votes for, 50,668 against and 1,872 abstentions.
Stockholders also approved an adjournment proposal to allow time to gather votes for the Issuance Proposal or ensure a quorum; that authority was not used. The second proposal received 43,642,799 votes for, 406,221 against and 15,726 abstentions.
Envoy Medical, Inc. (COCH) entered into a Dismissal Agreement with Atlas Merchant Capital SPAC Fund I LP on October 6, 2026, concerning litigation in the Delaware Court of Chancery. Under the agreement, all of Atlas’ claims will be dismissed with prejudice, and there will be no further proceedings. Envoy Medical and the other defendants are not required to make a payment to Atlas under the agreement.
Envoy Medical, Inc. (COCH) reports in this Schedule 13G/A Amendment No. 1 that Alta Partners LLC beneficially owns 2,054,011 shares of Class A common stock, all issuable upon exercise of warrants. This position represents 2.59% of the Class A common stock, with sole voting and dispositive power over all such shares.
Alta Partners LLC reports no shared voting or dispositive power and confirms that its ownership is 5 percent or less of the class. The filing is signed by Steven Cohen as Managing Member on September 14, 2026.
Envoy Medical, Inc. (COCH) reported that officer Robert Potashnick, CAO & VP of Finance, received a grant of 250,000 stock options on 2026-08-24 with an exercise price of $0.746 per share, expiring on 2036-08-24. According to the vesting terms, options to purchase 62,500 shares vest on 2027-08-24 and the remaining 187,500 shares vest pro rata on the 24th of each month thereafter for 36 months.
Potashnick also has an existing option covering 15,000 underlying shares at a $0.53 exercise price, plus direct holdings of 212,500 shares of Class A common stock. In addition, he holds warrants exercisable for 127,500 and 212,500 Class A shares at a $0.40 exercise price, which become exercisable upon shareholder approval and have expirations tied to key FDA milestones for Envoy Medical’s Acclaim CI Device.
Envoy Medical, Inc. reported second-quarter 2026 results and highlighted progress toward commercializing its fully implanted Acclaim cochlear implant. The company submitted the first of four modules of its modular PMA application to the FDA and plans to submit remaining modules on a rolling basis, with the fourth targeted in the second quarter of 2027. Subsequent to quarter end, Envoy reported positive 12‑month data for the first 10 Stage 1 trial participants and noted that the pivotal trial has surpassed the three‑month follow-up mark.
For the quarter ended June 30, 2026, net revenue was $51,000. Net loss attributable to common stockholders was $7.3 million, or $0.07 per share. As of June 30, 2026, cash was $19.7 million, supported by $30.0 million of proceeds from an issuance of Class A common stock, pre‑funded warrants and Series A warrants during the first half of 2026. Total assets were $23.9 million and stockholders’ equity was $3.3 million.
Envoy Medical, Inc. develops fully implanted hearing devices and remains a pre-revenue, development-stage company centered on its investigational Acclaim cochlear implant. For the three and six months ended June 30, 2026, it generated only $51k and $90k of net revenue, respectively, primarily from legacy Esteem implant components, while recording net losses of $5.98M and $10.33M.
Research and development spending was substantial at $3.13M for the quarter and $6.77M year-to-date, driving an operating loss of $11.53M for the first half. Operating cash outflow was $11.52M, but cash increased to $19.68M at June 30, 2026 from $3.74M at year-end, mainly due to the February 2026 equity offering, which raised $29.997M gross and $27.78M net and expanded Class A shares outstanding to 77.2M. Numerous warrants and preferred shares create a sizable potential dilution overhang.
Management explicitly states that existing cash is not sufficient to fund operations for 12 months after issuance of these financial statements, concluding that substantial doubt exists about the company’s ability to continue as a going concern. Plans rely on additional financing and potential warrant exercises. Clinically, all 56 pivotal Acclaim cochlear implant trial participants have been enrolled and activated, the first 10 have reached 12-month follow-up, all 56 have passed the 3‑month milestone, and the first module of the Premarket Approval application was submitted to the FDA.
Envoy Medical, Inc. has terminated its at-the-market equity facility, which had allowed the company to offer and sell up to $15 million of common stock from time to time. The termination, effective June 24, 2026, also ends the related At The Market Offering Agreement dated January 17, 2025.
The company framed this step as reflecting confidence in its current capital position. Existing Class A common stock and redeemable warrants continue to trade on Nasdaq under the symbols COCH and COCHW, respectively.
Envoy Medical updated its CEO compensation package. The board’s compensation committee approved a new base salary of $420,000 per year for Chief Executive Officer Brent Lucas, plus eligibility for a $105,000 target cash bonus tied to strategic goals for 2026 and 2027.
Lucas also received 1,000,000 stock options exercisable at $0.634 per share that vest over four years, and 1,000,000 restricted stock units. The RSUs will vest only if the FDA issues an approval, including conditional approval, for Envoy’s Acclaim cochlear implant during the period from June 19, 2026 to June 18, 2030.
Envoy Medical, Inc. filed a Form 4 showing that Chief Executive Officer Brent T. Lucas received significant new equity awards tied to regulatory milestones for the company’s Acclaim cochlear implant. On June 19, 2026, he was granted 1,000,000 Restricted Stock Units, each representing one share of Class A Common Stock. These RSUs will vest if the U.S. Food and Drug Administration grants approval (including conditional approval) for the Acclaim cochlear implant during the performance period from June 19, 2026 to June 18, 2030.
On the same date, Lucas was also granted 1,000,000 stock options to buy Class A Common Stock at an exercise price of $0.634 per share, expiring on June 19, 2036. The filing also lists his existing equity exposure, including 329,946 Class A Common shares held directly and multiple warrants and options with exercise prices ranging from $0.40 to $11.50 per share, which together show a substantial stake linked to the company’s long-term performance.
Envoy Medical, Inc. Chief Executive Officer Brent T. Lucas reported an acquisition of 32,856 shares of Class A Common Stock at $0.599 per share. These shares were acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). Following this grant, he directly holds 329,946 common shares.
Lucas also reports significant derivative positions. He holds warrants covering 62,500 and 37,500 underlying shares at an exercise price of $0.40 per share, and additional warrants for 110,987 shares at $11.50 per share expiring on September 29, 2028. Certain warrants become exercisable only upon shareholder approval of the underlying share issuance, and Series A-1 and A-2 warrants can expire earlier upon specified FDA-related milestones for the Acclaim CI Device.
In stock options, Lucas holds rights to buy 200,000 shares at $0.53 per share expiring on February 5, 2036, and 879,749 shares at $2.40 per share expiring on October 15, 2033. Footnotes describe vesting schedules for option blocks of 659,811 and 219,938 shares starting on October 15, 2023, and for blocks of 50,000 and 150,000 shares starting on February 5, 2027, with monthly pro rata vesting thereafter.